GENOMTEC

INVESTOR PRESENTATION

May 2025

GPW

Spółka notowana na
Giełdzie Papierów Wartościowych w Warszawie

Legal disclaimers

This document has been prepared for informational purposes only, contains only summary information and is not intended to be exhaustive, nor is it intended to be the sole basis for any analysis or evaluation. Genomtec SA makes no representations (express or implied) regarding the information presented in this document and no reliance should be placed on any information contained in this document, including the forecasts, estimates and opinions contained therein. Genomtec SA assumes no liability for any errors, omissions or irregularities contained in this document. It uses sources of information that Genomtec SA considers reliable and accurate, but there is no guarantee that they are exhaustive and fully reflect the facts. This document does not constitute advertising or an offer of securities in public trading. The document may contain forward-looking statements that constitute an investment risk or a source of uncertainty and may differ materially from actual results. Genomtec SA is not responsible for the effects of decisions made on the basis of this document. The responsibility rests solely with the user of the document. The work is protected by the Copyright and Related Rights Act. Reproduction, publication or distribution requires written consent of Genomtec SA

GENOMTEC

AGENDA

1. ABOUT Genomtec
2. Current operational activities
3. Current project status oncoSNAAT
4. Clinical trials
5. Q&A session

An international team, a combination of science and business

MANAGEMENT

Miron Tokarski

President of the Management Board, Co-founder of the Company

Co-creator of Genomtec technology and patents
Doctor of Medical Sciences in the field of molecular biology.
Honored by Forbes in the "Leaders of the Future" ranking.

Michał Wachowski

Member of the Management Board, Financial Director

14+ years of experience in: corporate finance, investment management and business consulting. He was an investment director in a Venture Capital fund.

International team of 20 experts

Two locations: Wroclaw (PL) and Kent (UK)

CO-FOUNDERS

Małgorzata Małodobra-Mazur

Chief Research Officer

Over 10 years of experience in molecular biology.
Head of the Department of Molecular Techniques at the Medical University of Wrocław. Author of scientific publications and co-author of Genomtec patents.

Henryk Roguszczak

Design Director

Author of patents and over 80 domestic and foreign scientific publications.
Previously an expert at the Wrocław University of Science and Technology at the Faculty of Microsystems, Electronics and Photonics.
Coordinator of research activities in the field of photonics.

An international team, a combination of science and business

GENOMTEC

Genomtec SA is a medical technology company founded in late 2016 with the goal of commercializing ultrafast, mobile point-of-care genetic testing platforms through the development of proprietary optical systems and technologies.Streamlined Nucleic Acid AmplificationTechnology (SNAAT®).

>20 Employees

Wroclaw

Kent, UK

GENOMTEC

Genomtec Technology

Genomtec SNAAT

Delivering innovative diagnostic technologies close to the patient – Point ofCare

SNAAT technology
(used, among others, in Genomtec ID visible above)

TEST SCOPE

- Infections
- Biomarkers
- Genetic variants

TESTING LOCATION

- Clinics
- Doctor's offices
- Emergency Department
- Patient transportation
- Airports

Genomtec is a MedTech company specializing in the development of advanced technologies in the field of genetic diagnostics.

OncoSNAAT– use of Genomtec technology in oncology

Long waiting time for the result, even up to **several weeks**

Transporting samples extends the waiting time for results and increases the chances **sample degradation**

Expensive analyzers taking up a significant amount of space

Multi-step analytical process requiring additional equipment and **trained staff**

High research costs >**$400 / test**

Next Generation Sequencing (NGS)

- Purchase cost of sequencer Illumina NovaSeq 6000 series is **approximately USD 985,000.**
- Waiting time for the result**-several weeks.**
- Necessity of **re-biopsy in 22.5%** cases.[1]
- Waiting time for the next biopsy **1.5 weeks.**[1]
- **Complications** as a result of biopsy occur in **7.3% of cases**.[1]
- **Single analysis cost $4,439** (average price for 5-50 and 50+ gene panels).[1]

Targeted diagnostics e.g. PCR

- Analyzer purchase cost **approximately USD 20,000.**
- Waiting time for the result**– a few days.**
- Necessity of **re-biopsy in 5.5%**cases.[1]
- **Cost of a single gene panel 443 - 1228 USD**.[1]

[1] JulieVanderpoel, Andrea L. Stevens, BrunoEmond, Marie-Helene Lafeuille,Annalise Hilts,PatrickLefebvre& Laura Morrison (2022) TotalcostoftestingforGenomics alterations associatedwithnext generation sequencingversusPolymerase chain reaction testing Strategies among patientswithmetastaticnon smallcell lung cancer,JournalofMedical Economics, 25:1, 457-468, DOI: 10.1080/13696998.2022.2053403

GENOMTEC

Development of OncoSNAAT project

Project development OncoSNAAT- PARP funding of PLN 21.6 million

1000+

Laboratory reactions performed
Development of an original method for diagnosing single-nucleotide changes

cftDNA

Selection of volumetric parameters of the sample
Work on a DNA isolation method begins

IP

Two patent applications for methods of detecting genetic variants
Planned extension of protection to international markets

21.6M PLN

FENG PARP funding amount - completion of the grant project planned for the 1st half of 2027.

Fundusze Europejskie dla Nowoczesnej Gospodarki

PARP Grupa PFR

The Genomtec project entitled: "Development of technology and an automatic system for detecting mutations in the field of clinical oncology based on the lab-on-chip solution and isothermal nucleic acid amplification techniques" was among 198 applications entered by PARP on the list of projects assessed positively in the SMART Path Measure FENG.01.01-IP.02-001/23/2023 under the European Funds for Modern Economy Programme.

*The recommended amount of funding for the project is approximately PLN 21.6 million with a total project budget of approximately PLN 40 million. If funding is received, the project will be implemented in the period from January 2024 to June 2027.

OncoSNAAT project milestones

Methods for diagnosing genetic variants

- Detection of multinucleotide genetic changes (patent pending September 2023)
- Detection of single-nucleotide genetic changes (patent pending January 2025)

A comprehensive approach enabling the diagnosis of common genetic variants that determine the selection of appropriate therapy (CDx) in oncological treatment and in the future also in other applications of accompanying diagnostics or diagnostics of diseases with a genetic basis.

Prototype of the card and analyzer

- Development of a method for isolating cancer genetic material from a blood sample – liquid biopsy – and selection of the sample volume.
- Creation of diagnostic kits enabling detection of specific genetic changes from the target sample type for the first oncology panel.
- Determining the technical requirements of the card microfluidic and handover to a subcontractor to create a prototype of the lab-on-chip system (for production using the injection molding method).
- Creating a card-compatible analyzer.
- Work on stabilization of reaction mixtures on the reaction card in order to develop a process for placing reagents on the card during production.

Internal tests

- Studies using, among others, clinical samples
- Possible modifications to the card and analyzer designs.
- Final version of the card microfluidicalong with the development of the production process, production line requirements, etc.

CLINICAL TRIALS

- Final card microfluidicwill be subject to clinical testing on material derived frombiobanks.
- In the final stage, full technical documentation will be prepared.
- Registration applications.

Scientific publication

GENOMTEC

scientific reports

View all journals | Search | Log in

Explore content | About the journal | Publish with us | Sign up for alerts | RSS feed

nature > scientific reports > articles > article

Article | Open access | Published: 08 March 2025

A new approach for the detection of genetic alterations utilizing modified loop-mediated isothermal amplification reaction (LAMP)

Aneta Cierzniak, Małgorzata Małodobra-Mazur & Miron Tokarski

Scientific Reports **15**, Article number: 8071 (2025) | Cite this article

1778 Accesses | Metrics

Abstract

The increasing use of genetic testing for personalised therapy, highlights the need for rapid, reliable diagnostics. Current methods are hindered by complex workflows, requiring advanced equipment, skilled personnel, and invasive tissue sampling. Loop-mediated isothermal amplification (LAMP) has emerged as a more efficient alternative to traditional PCR. LAMP eliminates thermal cycling, allowing faster, more cost-effective tests, and is less sensitive to inhibitors, enabling testing from minimally processed samples. Although LAMP is newer and has a longer assay development time than PCR, its potential in oncology, particularly for detecting genetic changes, is promising. We have developed a LAMP-based method for detecting genetic variations, optimized for point-of-care testing. This technique uses modified primers with alterations at the 3′ end of either F2 or B2 primers, ensuring specificity for altered sequences. The assay only produces a positive signal when the genetic variant is present, distinguishing it from wild-type DNA. Our findings demonstrate that this method has high specificity and sensitivity, even in samples with both wild-type and mutated material. Paired with a portable device, this LAMP-based diagnostic method could revolutionize genetic alteration detection, offering quicker results and improving treatment outcomes,

Download PDF

Sections | Figures | References

Conclusion

The LAMP technique has the potential to be successfully utilised for detection of several types of genetic variants, proven both by Genomtec and numerous other research groups. Due to its simple, fast, and low-cost diagnostic process, which does not require any sophisticated equipment or highly qualified personnel, the assay design approach developed by Genomtec is the perfect solution for point-of-care variant detection. Moreover, thanks to its ability to use a wide variety of biological samples, including liquid biopsy, minimally pre-processed or crude biological sample, the use of LAMP-based approach for point-of-care testing is both easy and convenient[39,43].

GENOMTEC

Current operational activities, M&A process status

2025 participation in leading business and scientific conferences

ESCMID Global 2025 (Austria)

BIO 2025 (USA)
(Planned)

Association for Diagnostics & Laboratory Medicine 2025 (USA)
(Planned Genomtec+Clairfield)

AMP 2025 (USA)
(Planned)

So far, we have conducted dozens of meetings and presentations of the Genomtec ID system, including with members of the Management Boards of potential partners in the M&A process, which were the starting point for the concluded NDA agreements.

Changes in the organizational structure of the company in connection with the M&A process

CURRENTLY:

GENOMTEC SA.

One company implements all projects

AFTER CHANGE:



Objective:

- Adaptation to buyers' needs.
- Accelerate M&A transactions.
- Increasing the value of the transaction.

Status:

- ✓ An individual tax interpretation was received.
- ✓ Preliminary consents have been received from the entities providing funding in the form of grants.
- ✓ Applications for registration of Companies in the National Court Register have been submitted
- ✓ Signing annexes with entities providing funding in the form of grants.
- ✓ Convening the EGM

POCT Genetic Testing Acquisitions Market

Genomtec capitalization = approx. $25m
Value of acquisitions of majority IVD platforms comparable to Genomtec ID = > $100m



INTELLECTUAL PROPERTY VALUATION

EUR 191.8 million gross
- 14-year protection period for the entire IP portfolio
- maintaining the current 100% success rate of converting patent applications to patents

EUR 109.3 million gross
- 8-year periodprotection of the current IP portfolio
- maintaining the current 100% success rate of converting patent applications to patents

EUR 95.7 million gross
- 8-year periodprotection of the current IP portfolio

The valuation applies only to intellectual property and does not take into account aspects such as:
- manufactured products,
- technical diagrams,
- Team,
- certificates and approvals received

DennemeyerConsulting GmbH
Valuation prepared by a renowned global company providing legal services in the field of patents, trademarks, data verification. The indicated values are estimates and should not be treated as a guaranteed value to the Issuer in the event of entering into any transaction.

Source: Deloitte Research, Genomtec, Merger Market.

M&A process status – synergy of business and R&D activities

Dozens of meetings

July 2023 - Present
Building a list of interested parties

Signing of NDAs

Signing of confidentiality agreements with a number of interested entities.

5 areas of interest

Exchange of data regarding technologies offered by both parties to NDA agreements.

- Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity).
- Costs of producing large-scale reaction cards.
- Leverage amplification technologies owned by potential partners.
- Possibilities of accelerating diagnostics using Genomtec ID.
- Methods for detecting genetic changes using isothermal technologies developed by Genomtec.

Cooperation with Lynx Final

- Analysis of the local IVD market, CDx
- Creating a localized presentation
- Contact with potential partners (from May 2025)

The state of the M&A process – technology

Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity)

- A series of tests and optimizations of algorithms controlling the non-contact heating system were carried out in an extended range of outside temperature and relative humidity.
- Temperature stabilization was achieved at +/- 1°C with a temperature difference between heating zones of up to 5°C. In combination with the use of 3 heating zones, we managed to cover the full temperature range for LAMP technology 60-70°C.



- Confirmed**no influence of changes in outside temperature and humidity**from the tested range on the efficiency of the heating system.
- The stability of the heating system was confirmed between subsequent analyses.
- The stability of the heating system over time has been confirmed.
- **Work is nearing completion on increasing stability to +/- 0.1°C with increased resolution – more heating zones.**
- Possibility to increase the resolution of temperature control – greater accuracy of analyses performed.

The state of the M&A process – technology

Possibilities of accelerating diagnostics using Genomtec ID.

- In conjunction with the work focused on reducing the cost of producing the reaction card, at the request of one of the potential partners, the possibilities of using new reagents to shorten the test time were investigated.
- **Several thousand reactions have been performed** allowing the use of proprietary primers from the RP5-Plex panel (influenza A, influenza B, RSV A, RSV B, SARS-CoV-2, M. pneumoniae, Ch. pneumoniae) in combination with new enzymes.
- The work also includes the development of a shortened protocol for isolating RNA viruses.
- The above activities aim to create a panel of viral infections with TAT ~15 min.

- **As part of the work carried out, the amplification time in the LAMP technique was shortened to <10 min. for viral pathogens along with an improvement in the detection limit.**
- Work is underway to validate the diagnostic process on a dedicated reaction card.



Amplification curves for influenza A (top), B (middle) at 50 GE/reaction and for influenza A at 10,000 GE/reaction (bottom)



Status of the M&A process – reduction of production costs

Costs of producing large-scale reaction cards.

- **Discussions were held with a number of partners specializing in the production of lab-on-chip microfluidic systems.**
- **Two independent quotes were obtained (CDMO partners) related to scaling up production in medium scale – semi-automatic line and large scale – automatic line.**
- **In order to define the function of the production lines, it was necessary to determine the requirements related to the stabilization of reagents allowing them to be stored at room temperature.**
  - Several hundred amplification reactions were performed to determine the impact of a number of stabilization processes on the diagnostic parameters of the tests.
- **The work carried out allowed us to determine the requirements for production lines, along with their equipment and costs.**
- **Achieved over 70% reduction in card production cost including reagents.**

- **Work also focused on optimizing reagent costs.**
  - Obtained**up to 80% reduction in reagent costs**.

GENOMTEC

CORPORATE FINANCIAL SITUATION 2024 AND SHARE ISSUE 1Q25

Capital increase (February-March 2025) PLN 11 million

- Issue of 1,542,556 series P shares
- Participation of investors, including institutional ones, in the ABB process
- On March 12, the EGM decision confirming the transaction was made, registration in the National Court Register on March 19.

SHAREHOLDING STRUCTURE 2024

Shareholder	Number of shares and votes at the General Meeting	Share in capital and votes at the general meeting
Leonarto Funds SCSp	1 650 620.00	12.39%
Miron Tokarsky	1 355 118.00	10.17%
The rest	10 318 832.00	77.44%
ALL	13 324 570.00	100.00%

TARGET SHAREHOLDING STRUCTURE AFTER SHARE ISSUE

Shareholder	Number of shares and votes at the General Meeting	% share in capital and votes at the general meeting
Leonarto Funds SCSp	1 650 620	11.1%
Miron Tokarsky	1 355 118	9.1%
New issue shares P	1 542 556	10.4%
The rest	10 318 832	69.4%
ALL	14 867 126	100.0%

GENOMTEC

SUMMARY

Summary

Innovative technology
12 patents and over 30 patent applications have been reported
2 methods for diagnostics of genetic changes

GMT ID's unique competitive position: cheap, portable, rapid test for detecting 5 pathogens
OncoSNAAT: Using the liquid biopsy technique - reducing complications, time to result and costs of care

Safe cash position
PLN 21.6 million of PARP subsidy – secures the project development until 2027

Product ready for scaling
Genomtec ID RP5-PLEX Panel
has EU CE-IVD certification valid until 31.12.2029*

Growing market
Point of care diagnosticsCare– USD 4.8 billion in 2027
Product portfolio development:
including oncology
Potential development area: food safety

High M&A values
– most often over USD 100 million
M&A process started
Advisors: Clairfield Partners LLC and ,Lynx,
IP valuation from Dennemeyer (EUR 191 million gross)

Source: Global Market Insights, 2020
*According to the European Commission proposal 2024/0021

GENOMTEC

investors@genomtec.com

https://genomtec.com/

Contact IR ccgroup
Agata Dzięciołowska
Michal Wierzchowski